A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response
Identifieur interne : 001134 ( Main/Exploration ); précédent : 001133; suivant : 001135A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response
Auteurs : Kawsar R. Talaat [États-Unis] ; Catherine J. Luke [États-Unis] ; Surender Khurana [États-Unis] ; Jody Manischewitz [États-Unis] ; Lisa R. King [États-Unis] ; Bridget A. Mcmahon [États-Unis] ; Ruth A. Karron [États-Unis] ; Kristen D. C. Lewis [États-Unis] ; JING QIN [États-Unis] ; Dean A. Follmann [États-Unis] ; HANA GOLDING [États-Unis] ; Kathleen M. Neuzil [États-Unis] ; Kanta Subbarao [États-Unis]Source :
- The Journal of infectious diseases [ 0022-1899 ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
Abstract
Background. Highly pathogenic avian influenza A(H5N1) causes severe infections in humans. We generated 2 influenza A(H5N1) live attenuated influenza vaccines for pandemic use (pLAIVs), but they failed to elicit a primary immune response. Our objective was to determine whether the vaccines primed or established long-lasting immunity that could be detected by administration of inactivated subvirion influenza A(H5N1) vaccine (ISIV). Methods. The following groups were invited to participate in the study: persons who previously received influenza A(H5N1) pLAIV; persons who previously received an irrelevant influenza A(H7N3) pLAIV; and community members who were naive to influenza A(H5N1) and LAIV. LAIV-experienced subjects received a single 45-μg dose of influenza A(H5N1) ISIV. Influenza A(H5N1)- and LAIV-naive subjects received either 1 or 2 doses of ISIV. Results. In subjects who had previously received antigenically matched influenza A(H5N1) pLAIV followed by 1 dose of ISIV compared with those who were naive to influenza A(H5N1) and LAIV and received 2 doses of ISIV, we observed an increased frequency of antibody response (82% vs 50%, by the hemagglutination inhibition assay) and a significantly higher antibody titer (112 vs 76; P=.04). The affinity of antibody and breadth of cross-clade neutralization was also enhanced in influenza A(H5N1) pLAIV-primed subjects. Conclusions. ISIV administration unmasked long-lasting immunity in influenza A(H5N1) pLAIV recipients, with a rapid, high-titer, high-quality antibody response that was broadly cross-reactive across several influenza A(H5N1) clades.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000092
- to stream PascalFrancis, to step Curation: 001D27
- to stream PascalFrancis, to step Checkpoint: 000143
- to stream Main, to step Merge: 001144
- to stream Main, to step Curation: 001134
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response</title>
<author><name sortKey="Talaat, Kawsar R" sort="Talaat, Kawsar R" uniqKey="Talaat K" first="Kawsar R." last="Talaat">Kawsar R. Talaat</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Center For Immunization Research, Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J." last="Luke">Catherine J. Luke</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Center for Biologics Evaluation and Research, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Manischewitz, Jody" sort="Manischewitz, Jody" uniqKey="Manischewitz J" first="Jody" last="Manischewitz">Jody Manischewitz</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Center for Biologics Evaluation and Research, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="King, Lisa R" sort="King, Lisa R" uniqKey="King L" first="Lisa R." last="King">Lisa R. King</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Center for Biologics Evaluation and Research, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcmahon, Bridget A" sort="Mcmahon, Bridget A" uniqKey="Mcmahon B" first="Bridget A." last="Mcmahon">Bridget A. Mcmahon</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Center For Immunization Research, Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Karron, Ruth A" sort="Karron, Ruth A" uniqKey="Karron R" first="Ruth A." last="Karron">Ruth A. Karron</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Center For Immunization Research, Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lewis, Kristen D C" sort="Lewis, Kristen D C" uniqKey="Lewis K" first="Kristen D. C." last="Lewis">Kristen D. C. Lewis</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>PATH</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jing Qin" sort="Jing Qin" uniqKey="Jing Qin" last="Jing Qin">JING QIN</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Follmann, Dean A" sort="Follmann, Dean A" uniqKey="Follmann D" first="Dean A." last="Follmann">Dean A. Follmann</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hana Golding" sort="Hana Golding" uniqKey="Hana Golding" last="Hana Golding">HANA GOLDING</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Center for Biologics Evaluation and Research, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Neuzil, Kathleen M" sort="Neuzil, Kathleen M" uniqKey="Neuzil K" first="Kathleen M." last="Neuzil">Kathleen M. Neuzil</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>PATH</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0154070</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0154070 INIST</idno>
<idno type="RBID">Pascal:14-0154070</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000092</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D27</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000143</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000143</idno>
<idno type="wicri:doubleKey">0022-1899:2014:Talaat K:a:live:attenuated</idno>
<idno type="wicri:Area/Main/Merge">001144</idno>
<idno type="wicri:Area/Main/Curation">001134</idno>
<idno type="wicri:Area/Main/Exploration">001134</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response</title>
<author><name sortKey="Talaat, Kawsar R" sort="Talaat, Kawsar R" uniqKey="Talaat K" first="Kawsar R." last="Talaat">Kawsar R. Talaat</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Center For Immunization Research, Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J." last="Luke">Catherine J. Luke</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Center for Biologics Evaluation and Research, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Manischewitz, Jody" sort="Manischewitz, Jody" uniqKey="Manischewitz J" first="Jody" last="Manischewitz">Jody Manischewitz</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Center for Biologics Evaluation and Research, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="King, Lisa R" sort="King, Lisa R" uniqKey="King L" first="Lisa R." last="King">Lisa R. King</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Center for Biologics Evaluation and Research, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcmahon, Bridget A" sort="Mcmahon, Bridget A" uniqKey="Mcmahon B" first="Bridget A." last="Mcmahon">Bridget A. Mcmahon</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Center For Immunization Research, Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Karron, Ruth A" sort="Karron, Ruth A" uniqKey="Karron R" first="Ruth A." last="Karron">Ruth A. Karron</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Center For Immunization Research, Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lewis, Kristen D C" sort="Lewis, Kristen D C" uniqKey="Lewis K" first="Kristen D. C." last="Lewis">Kristen D. C. Lewis</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>PATH</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jing Qin" sort="Jing Qin" uniqKey="Jing Qin" last="Jing Qin">JING QIN</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Follmann, Dean A" sort="Follmann, Dean A" uniqKey="Follmann D" first="Dean A." last="Follmann">Dean A. Follmann</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hana Golding" sort="Hana Golding" uniqKey="Hana Golding" last="Hana Golding">HANA GOLDING</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Center for Biologics Evaluation and Research, Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Neuzil, Kathleen M" sort="Neuzil, Kathleen M" uniqKey="Neuzil K" first="Kathleen M." last="Neuzil">Kathleen M. Neuzil</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>PATH</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases Food and Drug Administration</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Attenuated strain</term>
<term>Humoral immunity</term>
<term>Immune response</term>
<term>Infection</term>
<term>Influenza A</term>
<term>Influenza A virus</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term>
<term>Souche atténuée</term>
<term>Vaccin</term>
<term>Immunité humorale</term>
<term>Réponse immune</term>
<term>Infection</term>
<term>Grippe A</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background. Highly pathogenic avian influenza A(H5N1) causes severe infections in humans. We generated 2 influenza A(H5N1) live attenuated influenza vaccines for pandemic use (pLAIVs), but they failed to elicit a primary immune response. Our objective was to determine whether the vaccines primed or established long-lasting immunity that could be detected by administration of inactivated subvirion influenza A(H5N1) vaccine (ISIV). Methods. The following groups were invited to participate in the study: persons who previously received influenza A(H5N1) pLAIV; persons who previously received an irrelevant influenza A(H7N3) pLAIV; and community members who were naive to influenza A(H5N1) and LAIV. LAIV-experienced subjects received a single 45-μg dose of influenza A(H5N1) ISIV. Influenza A(H5N1)- and LAIV-naive subjects received either 1 or 2 doses of ISIV. Results. In subjects who had previously received antigenically matched influenza A(H5N1) pLAIV followed by 1 dose of ISIV compared with those who were naive to influenza A(H5N1) and LAIV and received 2 doses of ISIV, we observed an increased frequency of antibody response (82% vs 50%, by the hemagglutination inhibition assay) and a significantly higher antibody titer (112 vs 76; P=.04). The affinity of antibody and breadth of cross-clade neutralization was also enhanced in influenza A(H5N1) pLAIV-primed subjects. Conclusions. ISIV administration unmasked long-lasting immunity in influenza A(H5N1) pLAIV recipients, with a rapid, high-titer, high-quality antibody response that was broadly cross-reactive across several influenza A(H5N1) clades.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Washington (État)</li>
</region>
<settlement><li>Baltimore</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Talaat, Kawsar R" sort="Talaat, Kawsar R" uniqKey="Talaat K" first="Kawsar R." last="Talaat">Kawsar R. Talaat</name>
</region>
<name sortKey="Follmann, Dean A" sort="Follmann, Dean A" uniqKey="Follmann D" first="Dean A." last="Follmann">Dean A. Follmann</name>
<name sortKey="Hana Golding" sort="Hana Golding" uniqKey="Hana Golding" last="Hana Golding">HANA GOLDING</name>
<name sortKey="Jing Qin" sort="Jing Qin" uniqKey="Jing Qin" last="Jing Qin">JING QIN</name>
<name sortKey="Karron, Ruth A" sort="Karron, Ruth A" uniqKey="Karron R" first="Ruth A." last="Karron">Ruth A. Karron</name>
<name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name>
<name sortKey="King, Lisa R" sort="King, Lisa R" uniqKey="King L" first="Lisa R." last="King">Lisa R. King</name>
<name sortKey="Lewis, Kristen D C" sort="Lewis, Kristen D C" uniqKey="Lewis K" first="Kristen D. C." last="Lewis">Kristen D. C. Lewis</name>
<name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J." last="Luke">Catherine J. Luke</name>
<name sortKey="Manischewitz, Jody" sort="Manischewitz, Jody" uniqKey="Manischewitz J" first="Jody" last="Manischewitz">Jody Manischewitz</name>
<name sortKey="Mcmahon, Bridget A" sort="Mcmahon, Bridget A" uniqKey="Mcmahon B" first="Bridget A." last="Mcmahon">Bridget A. Mcmahon</name>
<name sortKey="Neuzil, Kathleen M" sort="Neuzil, Kathleen M" uniqKey="Neuzil K" first="Kathleen M." last="Neuzil">Kathleen M. Neuzil</name>
<name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001134 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001134 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:14-0154070 |texte= A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response }}
This area was generated with Dilib version V0.6.34. |